Pharmacologic treatment of disturbed sleep in the elderly

Harvard Review of Psychiatry

Volumn 16, Issue 5, 2008, Pages 271-278

  Salzman, Carl ^a,b,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^d NONE   (United States)

Author keywords

Antidepressants; Antipsychotics; Benzodiazepines; Elderly; Melatonin; Sleep; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; DIPHENHYDRAMINE; ESZOPICLONE; FLUOXETINE; FLURAZEPAM; HYPNOTIC AGENT; MELATONIN; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; QUETIAPINE; RAMELTEON; SERTRALINE; TEMAZEPAM; TIAGABINE; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ABSENCE OF SIDE EFFECTS; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; COORDINATION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; GERIATRIC PATIENT; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MEDICAL LITERATURE; MEMORY DISORDER; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MYOCLONUS; OFF LABEL DRUG USE; PARASOMNIA; PARKINSON DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW; SCHIZOPHRENIA; SHORT COURSE THERAPY; SIDE EFFECT; SLEEP DISORDER; SLEEP PATTERN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; BEHAVIOR THERAPY; BENZODIAZEPINES; COMBINED MODALITY THERAPY; DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; RECEPTORS, GABA-A; RECEPTORS, MELATONIN; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 52449104047     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220802432442     Document Type: Review

References (65)

1. Ancoli-Israel S. Sleep problems in older adults: putting myths to bed. Geriatrics 1997;52:20-30.
2. Ganguli M, Reynolds CF, Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: the movies project. J Am Geriatr Soc 1996;44:778-84.
3. Gillin JC, Ancoli-Israel. The impact of age on sleep and sleep disorders. In: Salzman C, ed. Clinical geriatric psychopharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;483-512.
4. Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003;51:671-7.
5. Craig D, Passmore AP, Fullerton KJ, et al. Factors influencing prescription of CNS medications in different elderly populations. Pharmacoepidemiol Drug Saf 2002;11:97-104.
6. Mah L, Upshur RE. Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician response. BMC Fam Pract 2002;3:9.
7. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Arch Gen Psychiatry 1985;42:225-32.
8. Morin CH, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia. JAMA 1999;281:991-9.
9. Reynolds CF III, Regestein Q, Nowell PD, Neylan T. Treatment of insomnia in the elderly. In: Salzman C, ed. Clinical geriatric psychopharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;513-42.
10. Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. Am J Med 2006;119:463-9.
11. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169.
12. Stewart R, Besset A, Bebbington P, et al. Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 2006;29:1391-7.
13. Reite M. Treatment of insomnia. In: Schatzberg AF, Nemeroff CB, eds. Essentials of clinical psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Publishing, 2006.
14. Roth TG, Roehrs TA, Koshorek GL, Greenblatt DJ, Rosenthal LD. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol 1997;17:401-6.
15. Hemmeter U, Müller M, Biscof R, Annen B, Holsboer-Trachsler E. Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology (Berl) 2000;147:384-96.
16. Morin CH, Bastien CH, Brink D, Brown TR. Adverse effects of temazepam in older adults with chronic insomnia. Hum Psychopharmacol 2003;18:75-82.
17. Salzman C. Treatment of anxiety and anxiety-related disorders. In: Salzman C, ed. Clinical geriatric psychopharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005;449-79.
18. Salzman C, Fisher J, Nobel K, et al. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992;7:89-93.
19. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 2004;19:437-54.
20. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005;66 suppl 2: 9-13.
21. Linsen SM, Zitman FG, Breteler MH. Defining benzodiazepine dependence: the confusion persists. Eur Psychiatry 1995;10:306-11.
22. Cook PJ. Benzodiazepine hypnotics in the elderly. Acta Psychiatr Scand Suppl 1986;74:149-58.
23. American Psychiatric Association. Task force report: benzodiazepine dependence, toxicity and abuse. Washington, DC: American Psychiatric Press, 1990.
24. National Institutes of Health. Drugs and insomnia. NIH Consensus Development Conference. Natl Inst Health Consens Dev Conf Summ 1984;4:1-9.
25. Kummer J, Guendel L, Linden J, et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993;21:171-84.
26. Shaw SH, Curson H, Coquelin JP. A double-blind study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992;20:150-61.
27. Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 2006;62:538-45.
28. Leger D, Scheuermaier K, Roger M. The relationship between alertness and sleep in a population of 769 elderly insomniacs with and without treatment with zolpidem. Arch Gerontol Geriatr 1999;29:165-73.
29. Olubodum JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 2003;56:297-304.
30. Allain H, Bentue-Ferrer D, Tarral A, Gandon JM. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 2003;59:179-88.
31. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993;15:127-36.
32. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Pharmacol 1992;43:597-601.
33. Rhodes SP, Parry P, Hanning CD. A comparison of the effects of zolpidem and placebo on respiration and oxygen saturation during sleep in the healthy elderly. Br J Clin Pharmacol 1990;30:817-24.
34. Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44-57.
35. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. Int J Geriatr Psychiatry 2000;15:704-12.
36. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-20.
37. Ancoli-Israel S, Richardson GS, Mangano RM. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005;6:107-13.
38. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633-42.
39. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91.
40. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720-7.
41. Garfinkel D, Laudon M. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995;346:541-4.
42. Haimov I, Lavie P. Potential of melatonin replacement therapy in older patients with sleep disorders. Drugs Aging 1995;7:75-8.
43. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603.
44. Peck JS, LeGoff DB, Ahmed I, Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons. Am J Geriatr Psychiatry 2004;12:432-6.
45. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Ping Shi J, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001;86:4727-30.
46. Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmocodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT I and MT 2. J Clin Pharmacol 2007;47:485-96.
47. Roth T, Seiden D, Wang-Weigand S, Zhang J. A2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005-14.
48. Johnson MW, Suess PE, Griffiths PP. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149-57.
49. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20:533-59.
50. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry 2000;8:298-306.
51. Reynolds CF 3rd, Smith GS, Dew MA, et al. Accelerating symptom-reduction in late-life depression. A double-blind, randomized, placebo-controlled trial of sleep deprivation. Am J Geriatr Psychiatry 2005;13:353-8.
52. Taylor MP, Reynolds CF, Frank E, et al. EEG sleep increases in later-life bereavement depression. A randomized double-blind, placebo-controlled evaluation of nortriptyline. Am J Geriatr Psychiatry 1999;7:41-7.
53. Wolf R, Dykierek P, Gattaz WF, et al. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry 2001;34:60-5.
54. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr; Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly patients. Am J Geriatr Psychiatry 2002;10:541-50.
55. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66:469-76.
56. Newhouse PA, Krishnan RR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000;61:559-68.
57. Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RM, Ascher JA. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61:196-202.
58. Staedt J, Dewes D, Danos P, Stoppe G. Can chronic neuroleptic treatment promote sleep disturbances in elderly schizophrenic patients? Int J Geriatr Psychiatry 2000;12:170-6.
59. Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S. Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia. Comparison of middle-aged and older adults. Am J Geriatr Psychiatry 2005;13:377-84.
60. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999;60:292-8.
61. Burchell BJ. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2003;60:1558.
62. Mathias S, Wetter TC, Steiger A, Lancel M. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001;22:247-53.
63. Roth T, Wright KP, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, doubleblind, placebo-controlled study. Sleep 2006;29:335-41.
64. Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE. Acute pharmacological effects of temazepam diphenhydramine, and valerian in healthy elderly subjects. J Clin Pyschopharmacol 2003;23:260-68.
65. Perras B, Wagner U, Born J, Fehm HL. Improvement of sleep and pituitary-adrenal inhibition after subchronic intranasal vasopressin treatment in elderly humans. J Clin Psychopharm 2003;23:35-44.